LABTRACE.ORG BETA LIVE
209 source polls this hour 70 615 articles collected last article 3m ago 1280 events on 2+ sources 0 embeddings/h feed queue 0 lag 297.5s
← all events
LT-035147 / first seen 2026-10-27 12:24 / last activity 3h ago

Intismeran Autogene Plus Pembrolizumab Versus Pembrolizumab Alone in High-Risk Resected Melanoma: 5-Year Update of the Randomized Phase IIb KEYNOTE-942 Study

measurement

heat
44 / 100 (raw 1.2)
velocity
0.0 independent sources per hour
solidity
80 / 100
sources
1 total, 1 independent
domain span
1 domain covered it

primary source

title
Intismeran Autogene Plus Pembrolizumab Versus Pembrolizumab Alone in High-Risk Resected Melanoma: 5-Year Update of the Randomized Phase IIb KEYNOTE-942 Study
venue
status
peer-reviewed
doi
10.1200/jco-26-00835
published
2026-09-10